

FILING BY "EXPRESS MAIL" UNDER 37 COR 1.10

EV 485023725 US Express Mail Label Number

16. Other items or information: Application Data Sheet

28 September 2004 Date of Deposit

Form PTO-1390-MOD U. S. (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER								
TRANSMITTAL LETTER TO 1	THE LINITED STATES	IB/G-32413A U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
DESIGNATED/ELECTED O										
CONCERNING A FILING UN	10/509502									
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED 28 March 2002 (28.03.02)								
PCT/ EP03/03215										
TITLE OF INVENTION TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES										
APPLICANT(S) FOR DO/EO/US ASCHER ET AL.										
Applicant herewith submits to the United States D	esignated/Elected Office (DO/EO/US) the	ne following items and other information:								
 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority 										
date.	date.									
A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a.										
 A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 										
Items 11. to 16. below concern document(s) or	information included.									
11. An Information Disclosure Statement und	der 37 CFR 1.97 and 1.98.									
12.	A separate cover sheet in compliance w	vith 37 CFR 3.28 and 3.31 is included.								
13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary	ry amendment.									
14. A substitute specification.										
15. A change of power of attorney and/or add	dress letter.	·								



U.S. APPLICATION NO. (ISKnown), s				ATTORNEY'S DOCKET NUMBER (B/G-32413A						
17. The following fe	es are submit	ted:						CAL	CULATION	IS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):										
Search Report has been prepared by the EPO or JPO										
International preliminary examination fee paid to USPTO (37 CFR 1.482)\$730										
\$730										
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$770										
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO										
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)						_				
ENTED ADDRODDIATE DASIC SEE AMOUNT -					\$	920				
ENTER APPROPRIATE BASIC FEE AMOUNT =						<u> </u>	 			
Surcharge of \$130 for furnishing the oath of declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						\$				
CLAIMS	NUMBE		NUMBÈR EXTR	₹A		RATE				
Total claims	18	- 20 =	0		Х	\$	18	\$		
Independent claims	6	-3 =	3		Х	\$	86	\$	258	
MULTIPLE DEPENDEN	T CLAIM(S) (if applicable)			+	\$	290	\$		
TOTAL OF ABOVE CALCULATIONS =						\$	1,178			
Reduction of 1/2 for filing		ity, if applical	ble. Verified Small	Entity	Statem	ent must al	so be		·	
filed (Note 37 CFR 1.9,	1.27, 1.28).							\$		
			·			SUBTO	TAL =	\$	1,178	
Processing fee of \$130 for furnishing the English translation later than 20 30 months from										
the earliest claimed prior	ity date (37 C	FR 1.492(f))					+	\$		
TOTAL NATIONAL FEE =					\$	1,178				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied						panied		-		
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						+	\$			
TOTAL FEES ENCLOSED =						\$	1,178			
						Amo	ount to be: refunded	\$		
							charged	\$		
A shook in the amount of the							J. L. I god			
 a.										
duplicate copy of this form is enclosed.										
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with										
Customer No. 001095, which is currently: Novartis Peter J. Waibel										
Corporate Intelle	ctual Propert	v				r Applicants	.			
One Health Plaza, Building 430 Reg. No. 43,228					•					
East Hanover, NJ 07936-1080 (862) 778-7951										